🔗 Share this article

Given that America proceeds with sweeping revisions to its vaccine guidelines, a particular individual appears somewhat surprisingly: Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations during the global health crisis and has concentrated on possible deaths after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Health officials were set to reveal sweeping revisions to the pediatric vaccine schedule recently, aligning the US with the Danish immunization schedule, according to reports – a major change that would put the US out of alignment with many the international standard with insufficient data for public health gain. This reveal has been delayed until the new year.

In place of Vinay Prasad, Høeg is listed to address the audience at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the office this year.

A New Direction at the FDA

This interim role might represent a strengthened alliance between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a greater focus upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for halting specific childhood immunization guidelines in the US to become more in line with the Danish model, a society with universal health coverage and a citizenry approximately the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccines – usually the domain of Dr. Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Høeg has no apparent experience in medication creation, oversight or leadership, which has been customary for past heads of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for running the CDER, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a large organization. She has no expertise in drug approvals.”

Previous heads of the center would “understand regulatory frameworks and the research of drug development”, said a former acting FDA commissioner. “Clearly, she lacks the type of experience that previous people who led the center have had.”

This division has an enormous workload at the agency, the former commissioner pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic drug division clears a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and more, and all of those need to be looked after,” she said. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major leadership aspect to the role, which manages over 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” she concluded.

Agency Reaction and Disputed Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this selection signifies more teamwork among agency officials on vaccines, a press secretary said that the “questions stem from inaccurate assumptions”.

“Her resume matches the functions of her role,” the spokesperson said, citing the period Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg inherits the agency head's new fast-track approval initiative, a contentious expedited therapy clearance system that reportedly concerned her predecessors. “How are these drugs being selected for this expedited pathway? Who makes the choices?” Dr. Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he remarked, “the agency looks to be trending towards laxer rules of pharmaceuticals, except for shots.”

Established Track Record on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, track record, Howard have noted. She authored a study using unconfirmed volunteer-provided data to assess the rate of myocarditis following Covid immunization. She advised the Florida top health official Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the new federal leadership encompassed revising regulations for new vaccines and ending “non-essential” vaccines, she stated following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding young men from obtaining COVID-19 vaccinations.

“She is an all-around true believer who commences with her preconceived notions and works backwards to accommodate the science in a extremely disingenuous, dishonest fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other contrarians, {like|